Major depressive disorder

Bragar Eagel & Squire, P.C. Is Investigating Relmada, DoubleVerify, Sanmina, and JinkoSolar and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, June 26, 2023
P.C, Depression, Life, SANM, JKS, Bank statement, Audit committee, DV, GAAP, MADRS, Report, MDD, News, NYSE, JinkoSolar, Major depressive disorder, Pharmaceutical industry, Cryptocurrency, Audit, Sanmina Corporation

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Additional information about each case can be found at the link provided.
  • Specifically, the REL-1017 treatment showed a MADRS reduction of 14.8 points at Day 28 versus 13.9 points for placebo, a higher-than-expected placebo response.
  • On this news, DoubleVerify’s share price fell $1.69, or 5.8%, to close at $27.22 per share on May 2, 2023, thereby injuring investors.

AltaPointe Health's Newest Facility in Clay County is Officially Open to Patients

Retrieved on: 
Friday, June 23, 2023
ACT, Life, Initiative, Taboo, Talladega, AL, Patient, Mental, Hospital, Environment, Mental health, NJIT Steel Bridge Team, Safety, Major depressive disorder, Nursing, Toy

ASHLAND, Ala., June 22, 2023 /PRNewswire-PRWeb/ -- AltaPointe Health, a leading provider of comprehensive mental health services, is pleased to announce the official opening of its brand-new clinic in Clay County. The Ashland, AL facility opened for patients on Monday, June 19, marking a significant milestone in the organization's ongoing commitment to improving access to mental healthcare.

Key Points: 
  • AltaPointe Health, a leading provider of comprehensive mental health services, is pleased to announce the official opening of its brand-new clinic in Clay County.
  • ASHLAND, Ala., June 22, 2023 /PRNewswire-PRWeb/ -- AltaPointe Health, a leading provider of comprehensive mental health services, is pleased to announce the official opening of its brand-new clinic in Clay County.
  • "The building is an investment in the community and shows AltaPointe's commitment to providing the utmost in mental healthcare to the people of Clay County," said Tuerk Schlesinger, AltaPointe Health CEO.
  • Clay County now offers more services than before AltaPointe and Cheaha Mental Health Center merged in 2016.

HMNC Brain Health Begins Phase 2 Study for Personalized Treatment of Stress-Axis Related Major Depressive Disorder (MDD)

Retrieved on: 
Tuesday, June 20, 2023
Olive, Anxiety, Brain, HPA, Depression, MDD, Patient, Grammatical mood, Psychiatry, Safety, Major depressive disorder, Pharmaceutical industry

The neuropeptide vasopressin plays a critical role in coordinating hormonal and behavioral adaptation to stress, and its elevated activity in the brain following repeated stressors may increase anxiety and depressive symptoms.

Key Points: 
  • The neuropeptide vasopressin plays a critical role in coordinating hormonal and behavioral adaptation to stress, and its elevated activity in the brain following repeated stressors may increase anxiety and depressive symptoms.
  • BH-200 directly targets the HPA-axis dysfunction and has demonstrated promising tolerability in previous clinical trials.
  • The Olive trial will evaluate the efficacy and safety of BH-200 in depressed patients.
  • ‘‘The commencement of our Phase 2 study is a crucial step in validating the safety and efficacy of this innovative treatment strategy.

Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Seagate, Chegg, and Relmada and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, June 20, 2023
P.C, CHGG, BIS, Depression, Seagate Technology, Bank statement, Bureau, Zein E. Obagi, ChatGPT, MADRS, Sale, Security, Seagate, HDD, FDP, MDD, WALD, Bureau of Industry and Security, Annual report, News, NYSE, Major depressive disorder, Cryptocurrency, Audit, Video game, Pharmaceutical industry, Huawei, Chegg

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Specifically, the Company is conducting an analysis regarding certain accounting issues in connection with the sale of certain Obagi products for the Vietnam market.
  • This historic foreign direct product enforcement case and settlement represents the largest standalone administrative penalty in BIS history.
  • Then, on May 1, 2023, Chegg held a conference call to discuss its results for the first quarter of 2023.

InvestmentPitch Media Video Discusses MindBio Therapeutics’ Clinical Trials of LSD-Microdosing Reveals Significant Positive Impact on Quality of Sleep

Retrieved on: 
Thursday, June 15, 2023
DSM, CSE, Depression, Pelvic floor dysfunction, Canadian Securities Exchange, Sleep, FSE, Medicine, Research, LSD, Weight gain, Creativity, Insomnia, Patient, Happiness, Big data, Addiction, Therapy, Mental health, News, Major depressive disorder, Pharmaceutical industry

The trials involved 80 participants, and a total of 3,231 nights of sleep data were analyzed.

Key Points: 
  • The trials involved 80 participants, and a total of 3,231 nights of sleep data were analyzed.
  • If these links are not enabled, please visit www.InvestmentPitch.com and enter “MindBio” in the search box.
  • Notably, LSD-Microdosing not only improves subjective feelings related to mood, happiness, energy, creativity, social connectivity, and wellness, but it also has a statistically significant impact on sleep quality.
  • For instance, conditions like pre-menstrual dysmorphic disorder are known to disproportionately affect sleep quality and have a significant impact on mental health.

Alzamend Neuro CEO Stephan Jackman to Participate on the “Mental Health, More Critical Than Ever” Panel at the Maxim Group’s Virtual Healthcare Conference

Retrieved on: 
Tuesday, June 13, 2023
General Health, Neurology, Mental Health, Health, Pharmaceutical, Major depressive disorder, Biotechnology, Science, Post-traumatic stress disorder, Standard of care, Knowledge, Conference, Bipolar disorder, Social media, Pharmaceutical industry

The “Mental Health, More Critical Than Ever” panel will begin at 2:00 PM ET on Tuesday June 20, 2023.

Key Points: 
  • The “Mental Health, More Critical Than Ever” panel will begin at 2:00 PM ET on Tuesday June 20, 2023.
  • Mr. Jackman looks forward to providing a brief overview of Alzamend’s therapeutic pipeline, followed by participation in an interactive/discussion/ Q&A session.
  • Maxim Group's Jason McCarthy and Joanne Lee will host an interactive panel discussion with the senior management from Alzamend, Intra-Cellular Therapies (ITCI), Reviva Pharmaceuticals (RVPH) and Bionomics (BNOX).
  • The exponential growth in knowledge and expertise in science and medicine continues to drive opportunities in the healthcare space.

RLMD INVESTOR NEWS: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – RLMD

Retrieved on: 
Saturday, June 10, 2023
Titan, Depression, MADRS, MDD, Advertising, News, I-Space (Chinese company), Major depressive disorder, Pharmaceutical industry, Cryptocurrency

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=15724 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

BetterLife Continues Progress on BETR-001 IND-Enabling Studies

Retrieved on: 
Thursday, June 8, 2023
GMP, GLP, CSE, DSM-IV codes, MDD, Patient, Physician, Dog, American College, Lysergic acid diethylamide, FDA, IND, ACP, Major depressive disorder, Pharmaceutical industry

VANCOUVER, British Columbia, June 08, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that the IND-enabling studies BetterLife’s 2-bromo-LSD (“BETR-001”) continue to progress.

Key Points: 
  • VANCOUVER, British Columbia, June 08, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that the IND-enabling studies BetterLife’s 2-bromo-LSD (“BETR-001”) continue to progress.
  • BetterLife has previously completed the preclinical pharmacological profiling of BETR-001, which showed that BETR-001 has robust activity in various depression/anxiety animal models without hallucinogenic activity.
  • The BETR-001 IND-enabling animal toxicology studies are now in various stages of completion.
  • Dr. Ahmad Doroudian, CEO of BetterLife commented, “We are very excited to be about mid-way through the BETR-001 IND-enabling toxicology studies, which are based on the guidance we received from the FDA from our pre-IND meeting.

Bragar Eagel & Squire, P.C. Is Investigating Relmada, Bowlero, and Integra and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, June 5, 2023
P.C, Depression, Integra, Lipopolysaccharide, MADRS, PAETEC Holding Corp., NYSE, MDD, News, Major depressive disorder, Pharmaceutical industry, Audit, Clothing, Bowlero Corporation

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Additional information about each case can be found at the link provided.
  • Before market opened on October 13, 2022, Relmada announced the results of its RELIANCE III study (REL-1017-303), evaluating the drug REL-1017 as a monotherapy for Major Depressive Disorder (MDD).
  • On this news, Integra’s stock price fell $10.24, or 20.2%, to close at $40.48 per share on May 23, 2023, thereby injuring investors.

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – RLMD

Retrieved on: 
Saturday, June 3, 2023
Titan, Depression, MADRS, MDD, Advertising, News, I-Space (Chinese company), Major depressive disorder, Pharmaceutical industry, Cryptocurrency

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=15724 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.